These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6133464)

  • 1. Neurotensin, schizophrenia, and common sense.
    Skrabanek P
    Am J Psychiatry; 1983 May; 140(5):658. PubMed ID: 6133464
    [No Abstract]   [Full Text] [Related]  

  • 2. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.
    Sharma RP; Janicak PG; Bissette G; Nemeroff CB
    Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.
    Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ
    Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurotensin receptor agonists and antagonists for schizophrenia.
    Robertson VB; Wilson MS
    Am J Psychiatry; 2005 Mar; 162(3):634; author reply 635. PubMed ID: 15741502
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome.
    Nemeroff CB; Bissette G; Widerlov E; Beckmann H; Gerner R; Manberg PJ; Lindstrom L; Prange AJ; Gattaz WF
    J Neuropsychiatry Clin Neurosci; 1989; 1(1):16-20. PubMed ID: 2577718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotensin agonists: potential in the treatment of schizophrenia.
    Boules M; Shaw A; Fredrickson P; Richelson E
    CNS Drugs; 2007; 21(1):13-23. PubMed ID: 17190526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotensin receptor agonists and antagonists for schizophrenia.
    Richelson E; Fredrickson PA; Boules MM
    Am J Psychiatry; 2005 Mar; 162(3):633-4; author reply 635. PubMed ID: 15741499
    [No Abstract]   [Full Text] [Related]  

  • 8. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
    Garver DL; Bissette G; Yao JK; Nemeroff CB
    Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotensin, schizophrenia, and antipsychotic drug action.
    Kinkead B; Nemeroff CB
    Int Rev Neurobiol; 2004; 59():327-49. PubMed ID: 15006494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced CSF neurotensin concentration in drug-free schizophrenic patients.
    Lindström LH; Widerlöv E; Bisette G; Nemeroff C
    Schizophr Res; 1988; 1(1):55-9. PubMed ID: 3154507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins.
    Griebel G
    Curr Pharm Des; 2015; 21(26):3807-12. PubMed ID: 26044977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotensin analogs indications for use as potential antipsychotic compounds.
    McMahon BM; Boules M; Warrington L; Richelson E
    Life Sci; 2002 Jan; 70(10):1101-19. PubMed ID: 11848295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An association study of the neurotensin receptor gene with schizophrenia and clozapine response.
    Huezo-Diaz P; Arranz MJ; Munro J; Osborne S; Makoff A; Kerwin RW; Austin J; O'Donovan M
    Schizophr Res; 2004 Feb; 66(2-3):193-5. PubMed ID: 15061255
    [No Abstract]   [Full Text] [Related]  

  • 14. Introduction: evaluating clinical trial data from schizophrenia research.
    Tamminga CA
    J Clin Psychiatry; 2001; 62 Suppl 9():3-4. PubMed ID: 11379829
    [No Abstract]   [Full Text] [Related]  

  • 15. First- vs second-generation antipsychotic drugs in schizophrenia.
    Andrade C; Kharawala S
    Arch Gen Psychiatry; 2007 Aug; 64(8):978-9; author reply 979-80. PubMed ID: 17679643
    [No Abstract]   [Full Text] [Related]  

  • 16. Newer antipsychotics in treatment-resistant schizophrenia.
    Marder SR
    Biol Psychiatry; 1999 Feb; 45(4):383-4. PubMed ID: 10071705
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of schizophrenia pharmacotherapy.
    Soumerai SB; Law MR
    Am J Psychiatry; 2007 Apr; 164(4):678; author reply 678-9. PubMed ID: 17403984
    [No Abstract]   [Full Text] [Related]  

  • 18. Sertindole versus haloperidol for schizophrenia.
    Balon R
    Am J Psychiatry; 1998 Sep; 155(9):1303-4. PubMed ID: 9734566
    [No Abstract]   [Full Text] [Related]  

  • 19. Sertindole versus haloperidol for schizophrenia.
    Mattes JA
    Am J Psychiatry; 1998 Sep; 155(9):1303; author reply 1303-4. PubMed ID: 9734567
    [No Abstract]   [Full Text] [Related]  

  • 20. Risperidone and clozapine for treatment-resistant schizophrenia.
    Meltzer HY
    Am J Psychiatry; 1999 Jul; 156(7):1126-7; author reply 1127-8. PubMed ID: 10401484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.